Ishara Investments LP Takes Position in Denali Therapeutics Inc. $DNLI

Ishara Investments LP bought a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 70,000 shares of the company’s stock, valued at approximately $1,156,000. Denali Therapeutics makes up approximately 1.3% of Ishara Investments LP’s investment portfolio, making the stock its 25th biggest position.

A number of other large investors also recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Denali Therapeutics by 8.9% in the fourth quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock valued at $215,586,000 after purchasing an additional 1,064,972 shares in the last quarter. Baillie Gifford & Co. lifted its holdings in Denali Therapeutics by 6.2% during the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock worth $203,253,000 after acquiring an additional 719,304 shares during the period. Temasek Holdings Private Ltd lifted its holdings in Denali Therapeutics by 30.9% during the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock worth $115,784,000 after acquiring an additional 1,657,142 shares during the period. State Street Corp lifted its holdings in Denali Therapeutics by 14.6% during the fourth quarter. State Street Corp now owns 6,263,371 shares of the company’s stock worth $103,408,000 after acquiring an additional 799,110 shares during the period. Finally, Norges Bank bought a new stake in Denali Therapeutics during the fourth quarter worth $84,525,000. Institutional investors own 92.92% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on DNLI shares. UBS Group reiterated a “buy” rating on shares of Denali Therapeutics in a report on Tuesday. Stifel Nicolaus lifted their price target on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Wall Street Zen upgraded Denali Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Robert W. Baird lifted their price target on Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Finally, Morgan Stanley dropped their price target on Denali Therapeutics from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Friday, May 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.25.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $23.49 on Thursday. The firm has a market cap of $3.73 billion, a PE ratio of -8.16 and a beta of 1.03. The stock’s fifty day moving average price is $19.94 and its two-hundred day moving average price is $19.52. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. Denali Therapeutics Inc. has a 1 year low of $12.58 and a 1 year high of $24.21.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. During the same period in the prior year, the business earned ($0.78) earnings per share. On average, equities research analysts forecast that Denali Therapeutics Inc. will post -2.77 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.